Responsif

Responsif GmbH is a German biotechnology company based in Erlangen that specializes in the development of innovative immunotherapies and diagnostic tools for oncology. The company's core technology platform utilizes recombinant polyoma virus-like particles (VLPs), specifically VP1-based capsoids, as a versatile delivery system for tumor antigens to stimulate the immune system. Responsif has developed therapeutic tumor vaccine candidates, such as those targeting survivin for indications like renal cell carcinoma and melanoma, and also provides specialized diagnostic reagents, including recombinant chicken Annexin V for the detection of apoptosis. Founded as a spin-off from the University of Erlangen-Nuremberg, the company has been a pioneer in VLP-based antigen delivery, although recent records indicate it has entered liquidation.